Screening for Barrett's esophagus (BE) is recommended for patients with chronic gastro-esophageal reflux disease (GERD) symptoms. Although EGD is commonly used for screening of BE, we have recently reported on excellent performance characteristics of string capsule endoscopy (SCE) in screening for BE. String capsule endoscopy (SCE) allows multiple uses after high-grade disinfection but its cost-effectiveness has not been tested. Aim: To evaluate the cost-effectiveness of SCE in screening for BE compared to EGD and PillCam Eso(PCE). Methods: A Markov model with a third party payer's perspective was built to compare different competing strategies of screening for BE and subsequent management in a hypothetical cohort of 50 year old patients with chronic GERD. In strategy I, no screening was performed and natural history of BE was modeled. In strategies II, III, and IV, SCE, PCE, and EGD, respectively were used for screening of BE. With SCE and PCE, positive findings were confirmed subsequently by EGD and biopsy. In the last three strategies, management of BE was based on the ACG guidelines. Incidence, Prevalence, and Natural history of BE was obtained from published information. Cost estimates were obtained from Medicare reimbursement data. Only discounted direct costs were considered. Incremental cost-effectiveness ratio (ICER) in terms of quality adjusted life years (QALYs) gained under each strategy was the main outcome compared. Results: Table shows the results of the baseline analysis. The SCE based strategy was more cost-effective compared to strategy of no screening and dominated the PCE based strategy. Although EGD based screening strategy yielded higher QALY, its ICER over SCE was prohibitively high. The results of the baseline analysis were robust and sensitivity analyses with important clinical variables, performance characteristics of different endoscopic procedures, and cost estimates did not change the conclusions. Conclusion: Screening of BE by string capsule endoscopy is more cost-effective compared to strategies of no screening, PillCam Eso, and importantly by EGD. Tabled 1Screening strategies Strategy Cost QALY ICER No screening 1,077 18.967 – SCE 1,980 18.991 36,383 compared to no screening PCE 2,380 18.990 Dominated EGD 2,499 18.992 592,847 compared to SCE Open table in a new tab
Read full abstract